Ukko
Latest round
- Series C
Last raised
- Jan 2026
Total raised
- $85M
Investors
- 9
About Ukko
Based in Tel Aviv, Israel, and founded in 2016, Ukko Inc. offers drugs intended to boost the immunity of an individual with food allergies and gluten-related disorders. In January 2026, Ukko Inc. The company operates as an artificial intelligence platform intended to uses patient samples, computational biology, immunology, and protein engineering to make proteins that do not trigger the immune system enabling proteins to be applied to the food and therapeutics markets. Ukko Inc. intendes to use the funds to enter clinical trials with its investigational therapeutic for peanut strategy. accelerate the development of its gluten that is designed for people with celiac and other gluten sentivities.
Who invested in Ukko
9 investors across 2 rounds
See all investors in Ukko
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ukko
Who invested in Ukko?
Ukko has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ukko raised?
Ukko has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Ukko last raise money?
Ukko's most recent round on record is a Series C, in Jan 2026.
What does Ukko do?
Based in Tel Aviv, Israel, and founded in 2016, Ukko Inc.
Where is Ukko headquartered?
Ukko is headquartered in Rehovot, Israel.
Which VCs invest in companies like Ukko?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Ukko's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Ukko? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.